Insmed (INSM) Selling, General & Administrative (2010 - 2026)
Powered by 
Analysis
Insmed (INSM) Selling, General & Administrative (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | SG&A (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 1.75 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 1.92 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 582.20 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 662.10 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -417.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 216.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 347.92 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 709.70 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 247.47 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -183.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 247.47 Mn |
| Mar 31, 2026 | 247.26 Mn |
| Dec 31, 2025 | 212.48 Mn |
| Sep 30, 2025 | 186.38 Mn |
| Jun 30, 2025 | 154.76 Mn |
| Mar 31, 2025 | 147.55 Mn |
| Dec 31, 2024 | 142.52 Mn |
| Sep 30, 2024 | 118.93 Mn |
| Jun 30, 2024 | 106.57 Mn |
| Mar 31, 2024 | 93.10 Mn |
| Dec 31, 2023 | 89.53 Mn |
| Sep 30, 2023 | 90.63 Mn |
| Jun 30, 2023 | 84.43 Mn |
| Mar 31, 2023 | 79.91 Mn |
| Dec 31, 2022 | 73.48 Mn |
| Sep 30, 2022 | 75.58 Mn |
| Jun 30, 2022 | 59.97 Mn |
| Mar 31, 2022 | 56.75 Mn |
| Dec 31, 2021 | 65.27 Mn |
| Sep 30, 2021 | 60.28 Mn |